China Company Transformation Indicator

Pharmaceutical Industry 2025

China Company Transformation Indicator

Pharmaceutical Industry 2025

Pharmaceutical companies ranking 2025

Note: The data used for the CCTI ranking of companies published by IMD is based on financial and non-financial data reported through official channels and reflect company performance up to the end of FY2023. Any events, developments, or changes occurring after this date are not reflected in the ranking. Users of this ranking should consider this limitation when interpreting the results.

China’s pharmaceutical sector: Innovation meets demographic-driven demand

The 2025 IMD China Company Transformation Indicator (CCTI) rankings for the pharmaceutical sector highlight three key success factors for leading pharmaceutical companies: Pharmaceutical Pipeline, R&D Efforts and Business Robustness. Top performers demonstrate financial strength, diversified product portfolios, and significant commitment to innovation.

However, challenges remain – the institutionalization of centralized drug procurement is putting pressure on margins, forcing companies to balance innovative development with cost efficiency and accessibility. Those with strong balance sheets and broad product portfolios have proven more adaptable to these regulatory shifts aimed at improving healthcare affordability.

Strategic government initiatives like the Pharmaceutical Industry High-Quality Development Action Plan (2023-2025) ,which was adopted by the State Council in August 2023, have played a crucial role in supporting pharmaceutical innovation, while the post-pandemic emphasis on preventive healthcare has created new opportunities, particularly in vaccines and biologics.

Read the full article

China biotech still dominated by international corporations

In our 2024 China Company Transformation Indicator, a dozen innovative national pharmaceutical and biotech companies entered the ranks as well as six traditional Chinese medicine makers.

FRI 2023 pharma tech fashion influencer - innovation, strategy and resilience - IMD Business School

Movers, shakers, and the rest: Tech, pharma, and fashion players ranked for future readiness

As the latest IMD Future Readiness Indicator is published, we take a closer look at the pioneers and innovators setting the stage for 2024.

Article

China's Apparel Sector -Domestic Champions

China’s apparel sector in 2025 sees local brands rise and global players adapt amid digital, Research & Development, and innovation-led growth.

Article

China's pharmaceutical sector – Demographic driven

Explore how innovation, R&D, and policy reforms are reshaping China’s pharmaceutical sector amid rising healthcare demand and demographic shifts.

Video

Zhou Yunjie – Haier – Innovation Management

Haier’s CEO Zhou Yunjie explains how the company’s innovative RenDanHeYi model empowers employees, drives global growth, and adapts to market changes.

Article

Honda and Nissan need more than a $58bn merger to compete with Chinese EVs

Honda and Nissan’s $58bn merger aims to compete with China’s EV dominance, but risks include cultural clashes, overlapping markets, and uncertain innovation outcomes.

Article

Financial trends 2025: tighten your (safety) belts for a roller-coaster ride

Global market shifts and turbulence in 2025 mean Chief Financial Officers must take into account inflation, trade tensions and shifting regulations to ensure long-term growth

Article

The next US administration must reassure China, not just deter it

Panelists debate the next US administration’s policy on China